StockData

Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$86.98−2.57 (-2.87%)

Close on Nov 17, 2026Market cap $4.87BP/E –Yield 0.00%

Dianthus Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Dianthus Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $2.04M, down 67.3% year over year. For fiscal 2025 it was $2.04M, down 67.3% from the year before. The highest annual figure on record is $6.24M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.04M-67.3%
FY2024Dec 31, 2024$6.24M+120.6%
FY2023Dec 31, 2023$2.83M–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$284.00K-78.6%
Q3 FY2025Sep 30, 2025$396.00K-81.8%
Q2 FY2025Jun 30, 2025$193.00K-89.6%
Q1 FY2025Mar 31, 2025$1.16M+33.1%
Q4 FY2024Dec 31, 2024$1.33M+190.2%
Q3 FY2024Sep 30, 2024$2.17M+135.1%
Q2 FY2024Jun 30, 2024$1.86M+58.8%
Q1 FY2024Mar 31, 2024$874.00K–
Q4 FY2023Dec 31, 2023$457.00K–
Q3 FY2023Sep 30, 2023$924.00K–
Q3 FY2022Sep 30, 2022$1.17M–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–

More Dianthus Therapeutics figures

See a number that looks wrong?